JP2024518097A - 刷子縁膜酵素切断可能リンカーを持つ葉酸受容体標的コンジュゲート並びにガンのイメージング及び治療における使用方法 - Google Patents
刷子縁膜酵素切断可能リンカーを持つ葉酸受容体標的コンジュゲート並びにガンのイメージング及び治療における使用方法 Download PDFInfo
- Publication number
- JP2024518097A JP2024518097A JP2023570221A JP2023570221A JP2024518097A JP 2024518097 A JP2024518097 A JP 2024518097A JP 2023570221 A JP2023570221 A JP 2023570221A JP 2023570221 A JP2023570221 A JP 2023570221A JP 2024518097 A JP2024518097 A JP 2024518097A
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- group
- acid
- alkyl
- following structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188910P | 2021-05-14 | 2021-05-14 | |
| US63/188,910 | 2021-05-14 | ||
| US202263318463P | 2022-03-10 | 2022-03-10 | |
| US63/318,463 | 2022-03-10 | ||
| PCT/US2022/029292 WO2022241279A2 (en) | 2021-05-14 | 2022-05-13 | Folate receptor-targeted conjugates with brush border membrane enzyme-cleavable linkers and methods of use in imaging and treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518097A true JP2024518097A (ja) | 2024-04-24 |
| JP2024518097A5 JP2024518097A5 (https=) | 2025-05-20 |
Family
ID=84028534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570221A Pending JP2024518097A (ja) | 2021-05-14 | 2022-05-13 | 刷子縁膜酵素切断可能リンカーを持つ葉酸受容体標的コンジュゲート並びにガンのイメージング及び治療における使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240335570A1 (https=) |
| EP (1) | EP4337265A4 (https=) |
| JP (1) | JP2024518097A (https=) |
| AU (1) | AU2022271866A1 (https=) |
| CA (1) | CA3217981A1 (https=) |
| MX (1) | MX2023013483A (https=) |
| WO (1) | WO2022241279A2 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004069159A2 (en) * | 2003-01-27 | 2004-08-19 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| WO2013130776A1 (en) * | 2012-02-29 | 2013-09-06 | Purdue Research Foundation | Folate receptor alpha binding ligands |
| WO2014149069A1 (en) * | 2013-03-15 | 2014-09-25 | Purdue Research Foundation | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
| US20190298843A1 (en) * | 2015-05-11 | 2019-10-03 | Purdue Research Foundation | Ligand ionophore conjugates |
| EP3430383B1 (en) * | 2016-03-16 | 2024-06-26 | On Target Laboratories, LLC | Ca ix-target nir dyes and their uses |
| CN118453888A (zh) * | 2016-11-16 | 2024-08-09 | 普渡研究基金会 | 配体离子载体共轭物 |
| WO2018178936A1 (en) * | 2017-03-30 | 2018-10-04 | Duke University | Radiolabeled biomolecules and their use |
| EP3996715A4 (en) * | 2019-07-08 | 2024-01-03 | Purdue Research Foundation | COMPOUNDS AND METHODS FOR TREATING AND PREVENTING FIBROTIC DISEASES AND CANCER |
-
2022
- 2022-05-13 CA CA3217981A patent/CA3217981A1/en active Pending
- 2022-05-13 AU AU2022271866A patent/AU2022271866A1/en active Pending
- 2022-05-13 JP JP2023570221A patent/JP2024518097A/ja active Pending
- 2022-05-13 WO PCT/US2022/029292 patent/WO2022241279A2/en not_active Ceased
- 2022-05-13 US US18/560,675 patent/US20240335570A1/en active Pending
- 2022-05-13 MX MX2023013483A patent/MX2023013483A/es unknown
- 2022-05-13 EP EP22808452.1A patent/EP4337265A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022241279A3 (en) | 2022-12-22 |
| CA3217981A1 (en) | 2022-11-17 |
| MX2023013483A (es) | 2024-02-27 |
| EP4337265A2 (en) | 2024-03-20 |
| WO2022241279A2 (en) | 2022-11-17 |
| AU2022271866A1 (en) | 2023-12-07 |
| US20240335570A1 (en) | 2024-10-10 |
| EP4337265A4 (en) | 2026-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7162592B2 (ja) | 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療 | |
| KR102902487B1 (ko) | 에반스 블루 유도체의 화학적 접합체 및 전립선 암 표적화를 위한 방사선 치료 및 조영제로서의 용도 | |
| TWI657827B (zh) | 用於正子斷層掃描之化合物 | |
| JP7097436B2 (ja) | エバンスブルー誘導体の化学的コンジュゲートおよびそれらの放射線治療剤および造影剤としての使用 | |
| JP7184775B2 (ja) | 黄体化ホルモン放出ホルモン受容体（ｌｈｒｈ－ｒ）コンジュゲートおよびその使用 | |
| CN101400371A (zh) | 具有取代的芳香部分及其衍生物的螯合共轭物 | |
| JP2024506644A (ja) | 標的送達に適用するための二価線維芽細胞活性化タンパク質リガンド | |
| JP7646637B2 (ja) | 画像化及び治療用組成物 | |
| Boss et al. | Comparative studies of three pairs of α-and γ-conjugated folic acid derivatives labeled with fluorine-18 | |
| US20120219495A1 (en) | Novel tetraaza macrocyclic compound, preparation method thereof and use thereof | |
| EP3918006A2 (en) | Conjugates of bivalent evans blue dye derivatives and methods of use | |
| JP2017530129A (ja) | ツブリシン複合体を用いた癌の治療方法 | |
| WO2024193724A1 (zh) | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 | |
| JP7027325B2 (ja) | 炭酸無水酵素ｉｘを標的とする薬剤および方法 | |
| CA2643145C (en) | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates | |
| CN117642184A (zh) | 具有刷状缘膜酶可裂解接头的叶酸受体靶向缀合物以及在癌症成像和治疗中的使用方法 | |
| JP2018512390A (ja) | Ｐｓｍａリガンド−チューブリシン化合物を用いた癌の処置方法 | |
| JP2024518097A (ja) | 刷子縁膜酵素切断可能リンカーを持つ葉酸受容体標的コンジュゲート並びにガンのイメージング及び治療における使用方法 | |
| JP6959142B2 (ja) | Ｍｃ１ｒを標的とする放射線療法用作用物質およびコンパニオンイメージング作用物質 | |
| KR20230171964A (ko) | 폴레이트 수용체-표적화된 방사선 요법제 및 이의 용도 | |
| WO2026027771A1 (en) | Alpha v beta 6-integrin binding cyclopeptides with non-natural amino acids, and conjugates thereof | |
| HK40099290A (zh) | 配体及其用途 | |
| CN101389355A (zh) | 双功能间苯二酚、硫代间苯二酚和二硫代间苯二酚衍生物金属螯合共轭物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20250115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250512 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250512 |